Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)

Condition:   Secondary Progressive Multiple Sclerosis
Interventions:   Drug: BAF312;   Drug: Baseline disease modifying therapies (DMTs)
Sponsor:   Novartis Pharmaceuticals
Active, not recruiting